STERIS plc (STE) Stock Price Quote, News & Filings

Summary

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.

Website

www.steris.com

Location

Mentor, L2, US

Phone353 1 232 2000

Employees17,937

CEODaniel A. Carestio

Sector

Materials

Industry

Paper & Forest Products

IPO DateJun 1, 1992

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… ip roles in marketing, sales, and global general management for the imaging and image-guided therapy businesses at Philips Healthcare. Earlier in his career, he held positions in finance where he was a group controller at STERIS Corporation before he pivoted into operations and served as Vice President of Operations. Mr. Fabian holds a Bachelor of Arts degree in Economics from the University of Michigan and an MBA from the University of Pittsburg …
Profound Medical Corp.STERIS plc·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·12 Nov
… ook forward to supporting him and the team as Executive Chairman.” Mr. Fabian brings more than 29 years of experience across medical imaging and medical devices. Before joining Profound, he served as Chief Executive Officer of FUJIFILM Sonosite. His previous roles included senior commercial and general management positions at Philips Healthcare, Vice President of Sales at Noetix Corporation and Vice President of Operations at STERIS Corporation.
Profound Medical Corp.STERIS plc·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·5 Nov
… to oversee the search for a permanent Chief Executive Officer. Mr. Rosebrough, age 72, has served as a member of the Board and its Corporate Governance and Nominating Committee since January 2026. He is CEO Emeritus of STERIS plc (NYSE: STE), a global medical device business focused on infection prevention products and services, where he served as Chief Executive Officer from 2007 to 2021. Mr. Rosebrough’s career also includes nearly two decades …
COOPER COMPANIES, INC.STERIS plc·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
Mr. Rosebrough has served on the Company’s Board and Corporate Governance and Nominating Committee since January 2026, and he is CEO Emeritus of STERIS plc (NYSE: STE), a global medical device business focused on infection prevention products and services. Mr. Rosebrough brings 40 years of experience in the medical device industry, including 25 years as a CEO, having led organizations from startups to multi-billion-dollar global enterprises and f …
COOPER COMPANIES, INC.STERIS plc·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
MiniMed’s sole suppliers include Convatec Group plc for the infusion sets used in MiniMed’s insulin pumps, Forj Medical (f/k/a Intricon Corporation) for transmitters, and Steris plc and Steri-Tech Inc. for sterilization services. MiniMed’s dependence on such sole suppliers subjects it to possible risks of shortages, interruptions, and price fluctuations. Certain of MiniMed’s sole suppliers are subject to regulation by the U.S. FDA and other regul …
MiniMed Group, Inc.STERIS plc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·5 Oct
MiniMed’s sole suppliers include Convatec Group plc for the infusion sets used in MiniMed’s insulin pumps, Forj Medical (f/k/a Intricon Corporation) for transmitters, and Steris plc and Steri-Tech Inc. for sterilization services. MiniMed’s dependence on such sole suppliers subjects it to possible risks of shortages, interruptions, and price fluctuations. Certain of MiniMed’s sole suppliers are subject to regulation by the U.S. FDA and other regul …
MiniMed Group, Inc.STERIS plc·S-4 - Registration statement (business combination)·Q3 26·14 Sep

Key Stats

Trading

Px/Chg 1D$208.54 / -0.38%

Prev Close$226.83

% of 52Wk H83.35%

Avg Volume825.20K

Beta0.38

Mkt Cap20.32B

FD Mkt Cap21.89B

Float

Shrs Out/Float97.46M / 97.13M

Short Float0.02%

Days to Cover2.34

Stock Repurchased$235.50M

Current Valuation

EV21.98B

EV/EBITDA12.03

EV/Sales3.70

P/B2.83

P/S3.42

FCF Yield1.21%

ROE10.93%

ROA7.31%

Current Ratio2.09

Dividend

Cash$0.63

Yield118.46%

Yield (TTM)118.46%

Estimates

P/E25.98

Est P/E0.00

Est EPS2.85

Est PEG0.00

Valuation

Metric	5Yr Avg	Aug '22	Aug '23	Aug '24	Aug '25	Oct '26
PRICE-BASED RATIOS
Price / Earnings	119.59	84.77	210.71	60.99	149.23	92.26
Price / Sales	8.37	4.90	4.97	4.49	14.68	12.80
Price / Book Value	3.33	3.17	3.71	3.66	3.29	2.83
Price / Free Cash Flow	68.83	52.05	57.10	37.64	114.48	82.89
ENTERPRISE VALUE METRICS
Enterprise Value	24,249.6	23,619.3	25,602.4	26,259.1	23,782.2	21,984.9
Enterprise Value / Sales	9.25	5.59	5.64	5.11	16.06	13.84
Enterprise Value / EBITDA	32.80	23.40	19.05	18.59	70.62	32.33
Enterprise Value / EBIT	58.96	51.76	32.36	31.00	110.91	68.79

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Mar '22	Mar '23	Mar '24	Mar '25	Mar '26
INCOME STATEMENT
Revenue	8.9%	4,223.4	4,536.3	5,138.7	5,459.5	5,935.9
Gross Income	8.7%	1,883.0	1,980.7	2,218.2	2,402.8	2,626.5
EBITDA	12.1%	1,009.4	1,344.0	1,412.4	1,358.7	1,594.5
EBIT	24.8%	456.3	791.1	847.2	882.5	1,108.0
Net Income	33.9%	243.9	107.0	378.2	614.6	785.1
EPS (Diluted)	33.7%	2.48	1.07	3.81	6.20	7.93
BALANCE SHEET
Cash & ST Inv	6%	348.3	208.4	207.0	171.7	439.6
Total Assets	-1.5%	11,423.6	10,821.8	11,063.7	10,146.8	10,737.2
Total Liabilities	-7.7%	4,879.0	4,734.7	4,748.4	3,531.1	3,540.0
Total Shareholder Equity	2.4%	6,532.4	6,077.2	6,302.2	6,603.4	7,183.6
CASH FLOW
Net Operating Cash Flow	18.3%	684.8	756.9	973.3	1,148.1	1,341.4
Cap Ex	6.4%	-287.6	-362.0	-360.3	-370.1	-369.0
Free Cash Flow	25.1%	397.2	395.0	612.9	778.0	972.4

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		262.59
Basic Shares		97.46
Market Cap		25,591.4
Diluted Shares		97.60
Fully Diluted Shares Outstanding		97.60
Fully Diluted Market Cap		25,628.8
+Consolidated Debt		243.1
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-531.1
−Short-term Investments		-
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		25,303.4

Segment data

Revenue

by Products and services

Product52%
Service48%